Napredna pretraga

Pregled bibliografske jedinice broj: 787356

Influence of CCR5Δ32 gene mutation on interferon-beta treatment response in multiple sclerosis


Ristić, Smiljana; Mikulčić, Mateja; Starčević Čizmarević, Nada; Lovrečić, Luca; Lavtar, Polona; Sepčić, Juraj; Šega Jazbec, Saša; Kapović, Miljenko; Peterlin, Borut
Influence of CCR5Δ32 gene mutation on interferon-beta treatment response in multiple sclerosis // Book of abstracts, 11th Balkan Congress of Human Genetics
Beograd, Srbija, 2015. (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
Influence of CCR5Δ32 gene mutation on interferon-beta treatment response in multiple sclerosis

Autori
Ristić, Smiljana ; Mikulčić, Mateja ; Starčević Čizmarević, Nada ; Lovrečić, Luca ; Lavtar, Polona ; Sepčić, Juraj ; Šega Jazbec, Saša ; Kapović, Miljenko ; Peterlin, Borut

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Book of abstracts, 11th Balkan Congress of Human Genetics / - , 2015

Skup
11th Balkan Congress of Human Genetics (11th BCHG)

Mjesto i datum
Beograd, Srbija, 17-20.09.2015

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Multiple sclerosis; CCR5 Δ32; Interferon-β; Treatment responsiveness

Sažetak
Interferon beta (IFN-β) is widely used as the first-line disease-modifying treatment for multiple sclerosis (MS). However, response to IFN-β is largely heterogeneous, and a significant number of MS patients (20-50%) continue to experience clinical and MRI disease activity despite treatment. Identification of biomarkers that predict responsiveness to IFN-β is important to define therapy strategies. The aim of this study was to analyze the association of CCR5Δ32 mutation with presence or absence of clinical response to IFN-β treatment in Croatian and Slovenian MS patients. We genotyped 161 IFN-β-treated patients with relapsing-remitting or secondary-progres¬sive MS. Based on clinical criteria for efficiency of MS treatment, patients were classified as responders, Rs (N=93) and nonresponders, NRs (N=68). 32 bp deletion in the CCR5 gene was detected using one-step PCR. No significant differences between Rs and NRs in CCR5 allele (p=0, 826) and genotype (p=0, 823) frequencies were observed. Also, in stratifying MS patients by gender or disease course, no significant differences in allele and genotype distributions between Rs and NRs were found. Our results indicate that the carriage of CCR5Δ32 mutation was not associated with IFN-β treatment response in Croatian and Slovenian MS patients.

Izvorni jezik
Engleski